Biotechnology company Dualitas Therapeutics has launched from stealth with a $65 million (£48 million) Series A financing round to develop next-generation bispecific antibodies (BsAbs). 

The company’s financing is co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly and Company (Lilly), and Alexandria Venture Investments. 

The funds will be used to advance a portfolio of next-generation bispecific antibodies (BsAbs), including lead programmes DTX-103 in allergic disease and DTX-102 for autoimmune disease, and to accelerate the development of Dualitas’ proprietary DualScreen BsAb discovery engine.

Unlike traditional, typically narrow, bispecific discovery approaches that pursue incremental gain, DualScreen operates at combinatorial scale to functionally identify candidates with highly differentiated activity, including through cell-surface proximity mechanisms, across the unexplored co-target space.  
 
“DTX-103 and DTX-102 demonstrate compelling preclinical profiles when benchmarked to commercially available therapies,” said Rich Murray, Interim CEO and Board Member of Dualitas. “Current therapies for patients with allergic and autoimmune diseases leave important needs unmet, such as faster onset of action and more meaningful clinical benefit. Our lead programmes, discovered from the DualScreen bispecific antibody discovery engine, are a new generation of bispecific antibodies aimed at addressing these patient needs.”

Alicia Levy, Venture Partner at Versant Ventures and Dualitas Board Member, added: “With the Series A proceeds, Dualitas is now well-positioned to maximize the potential of its technology through a two-pronged strategy: advancing a pipeline that capitalizes on cell-surface proximity biology mechanisms, and pursuing strategic partnerships that extend the reach and impact of DualScreen-discovered candidates.” 

 

Bruno Quinney, Content Team, DDW